BSX vs BDX stock comparison
Boston Scientific vs. Becton Dickinson & · data as of November 13, 2026
Boston Scientific (BSX) has a market value of about $64.3B, Becton Dickinson & (BDX) about $59.4B. Over their latest twelve months Boston Scientific had revenue of $21.1B and Becton Dickinson & $19.5B.
On our five checks Boston Scientific scores higher: 3.0 out of 5 (average) against 2.0 (weak).
By area, the stronger company is Boston Scientific on value; Boston Scientific on future growth; Boston Scientific on financial health; Becton Dickinson & on shareholder returns.
Boston Scientific is cheaper on earnings (P/E 18.8 vs. 43.1).
Boston Scientific leads on 18 of the compared lines and Becton Dickinson & on 4.
Side by side
| BSX | BDX | |
|---|---|---|
| Size and price | ||
| Market cap | $64.3B | $59.4B |
| Share price | $44.34 | $218.03 |
| Score | ||
| Overall score (of 5) | 3.0 | 2.0 |
| Value | 3 | 0 |
| Future growth | 5 | 2 |
| Track record | 2 | 2 |
| Financial health | 4 | 2 |
| Shareholder returns | 1 | 4 |
| Valuation | ||
| P/E (TTM) | 18.8 | 43.1 |
| Forward P/E | 14.4 | 17.5 |
| Price / free cash flow | 19.3 | 22.0 |
| Price / sales | 3.1 | 3.1 |
| EV / EBITDA | 14.1 | 14.3 |
| PEG | — | 2.61 |
| DCF value vs. price | −58% | −41% |
| Business | ||
| Revenue | $21.1B | $19.5B |
| Net income | $3.5B | $1.1B |
| Free cash flow | $3.3B | $2.7B |
| Net margin | 16.6% | 5.9% |
| Gross margin (5-yr avg.) | 68.9% | 44.6% |
| ROIC (5-yr avg.) | 5.9% | 4.8% |
| Growth | ||
| Revenue growth (1 yr) | 19.9% | 8.2% |
| Revenue growth (5 yrs, per year) | 15.2% | 6.3% |
| EPS growth (5 yrs, per year) | — | 16.5% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$11.3B | -$16.1B |
| Dividend yield | None | 1.94% |
| Shareholder yield | 0.0% | 3.6% |
| Analysts | ||
| Upside to average target | +12% | +4% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: BSX TTM to September 30, 2026, BDX TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Boston Scientific or Becton Dickinson &?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Boston Scientific scores 3.0 out of 5 and Becton Dickinson & 2.0; the table shows where each one is stronger.
Is Boston Scientific cheaper than Becton Dickinson &?
On trailing earnings, Boston Scientific trades at a P/E of 18.8 and Becton Dickinson & at 43.1, so Boston Scientific is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Boston Scientific or Becton Dickinson &?
Over five years Boston Scientific grew revenue about 15.2% a year and Becton Dickinson & about 6.3% a year.
Which pays a higher dividend?
Boston Scientific yields nothing (no dividend) and Becton Dickinson & 1.94%.
Full Boston Scientific analysis → Full Becton Dickinson & analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.